IL1B and systemic-onset juvenile idiopathic arthritis: Canakinumab, a human monoclonal anti-human IL-1β antibody, is approved in the EU for the treatment of active AOSD and SJIA, following an inadequate response to NSAIDs and systemic corticosteroids [14]; according to the US FDA label, canakinumab is indicated for active SJIA [15].